Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Banco Santander SA (SAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Banco Santander SATrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Banco Santander SA vs State Street SPDR S&P Biotech ETF — how do they compare? Banco Santander SA trades at $14.85 (market cap $211.63B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Banco Santander SA pays a 1.89% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

SANXBI
Market Cap
$211.63B
Sector
FinancialsBroad Market / Factor
52-Week High
$14.71$164.28
52-Week Low
$9.37$86.92
Dividend Yield
1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Banco Santander SA

Banco Santander (SAN) trades at $14.83, up 0.92% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, beating estimates in Q1 but missing in Q2, while net income grew to $14.10 billion in 2025. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, enhancing its U.S. footprint.

Outlook is supported by analyst consensus (64% buy ratings) and record profitability, but risks include volatile earnings, high debt levels, and integration challenges from acquisitions. The stock's valuation appears reasonable with a P/E of 14.4, offering potential for growth if execution remains strong amid economic uncertainties.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About Banco Santander SA

Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.

Read more on SAN

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI